302 related articles for article (PubMed ID: 29551750)
21. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
22. In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP.
Groppe JC; Wu J; Shore EM; Kaplan FS
Cells Tissues Organs; 2011; 194(2-4):291-5. PubMed ID: 21525719
[TBL] [Abstract][Full Text] [Related]
23. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.
Le VQ; Wharton KA
Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
[TBL] [Abstract][Full Text] [Related]
25. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
Shore EM; Kaplan FS
Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
[TBL] [Abstract][Full Text] [Related]
26. Drosophila models of FOP provide mechanistic insight.
Le V; Anderson E; Akiyama T; Wharton KA
Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
[TBL] [Abstract][Full Text] [Related]
27. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
Ravazzolo R; Cappato S; Bocciardi R
Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
[TBL] [Abstract][Full Text] [Related]
28. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
29. ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex.
Williams E; Riesebos E; Kerr G; Bullock AN
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33572801
[TBL] [Abstract][Full Text] [Related]
30. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
[TBL] [Abstract][Full Text] [Related]
31. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
32. [Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].
Katagiri T
Clin Calcium; 2010 Aug; 20(8):1204-11. PubMed ID: 20675931
[TBL] [Abstract][Full Text] [Related]
33. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
[TBL] [Abstract][Full Text] [Related]
34. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM
Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241
[TBL] [Abstract][Full Text] [Related]
35. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.
Kaplan FS; Kobori JA; Orellana C; Calvo I; Rosello M; Martinez F; Lopez B; Xu M; Pignolo RJ; Shore EM; Groppe JC
Am J Med Genet A; 2015 Oct; 167A(10):2265-71. PubMed ID: 26097044
[TBL] [Abstract][Full Text] [Related]
36. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.
Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC
J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499
[TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Sanchez-Duffhues G; Williams E; Goumans MJ; Heldin CH; Ten Dijke P
Bone; 2020 Sep; 138():115472. PubMed ID: 32522605
[TBL] [Abstract][Full Text] [Related]
38. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
[TBL] [Abstract][Full Text] [Related]
39. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
Takahashi M; Katagiri T; Furuya H; Hohjoh H
Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
[TBL] [Abstract][Full Text] [Related]
40. Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.
Kaplan FS; Al Mukaddam M; Stanley A; Towler OW; Shore EM
Bone; 2020 Nov; 140():115539. PubMed ID: 32730934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]